Immunocore Holdings plc

Immunocore Holdings plc a commercial-stage biotechnology company engages in the development of immunotherapies for the treatment of cancer infectious and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also developing other programs for oncology comprise tebentafusp that is in Phase 2/3 clinical trial in patients with advanced melanoma; IMC-F106C which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising cutaneous melanoma ovarian non-small cell lung cancer and endometrial; IMC-T119C for multiple solid tumor cancers; IMC-P115C for multiple solid tumor cancers; and IMC-R117C which is for a range of tumors including colorectal gastro-esophageal and pancreatic cancers. In addition the company's programs for infectious diseases include IMC-I109V which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in Phase 1 clinical trial for patients with human immunosuppression virus. Further it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon the United Kingdom.